ES2864049T3 - Anticuerpos selectivos para protofibrillas/oligómeros de amiloide-P truncado en el extremo N - Google Patents
Anticuerpos selectivos para protofibrillas/oligómeros de amiloide-P truncado en el extremo N Download PDFInfo
- Publication number
- ES2864049T3 ES2864049T3 ES10739701T ES10739701T ES2864049T3 ES 2864049 T3 ES2864049 T3 ES 2864049T3 ES 10739701 T ES10739701 T ES 10739701T ES 10739701 T ES10739701 T ES 10739701T ES 2864049 T3 ES2864049 T3 ES 2864049T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- protofibrils
- protofibril
- oligomers
- terminally truncated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22110509P | 2009-06-29 | 2009-06-29 | |
| PCT/IB2010/052947 WO2011001366A1 (en) | 2009-06-29 | 2010-06-29 | N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2864049T3 true ES2864049T3 (es) | 2021-10-13 |
Family
ID=42832352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10739701T Active ES2864049T3 (es) | 2009-06-29 | 2010-06-29 | Anticuerpos selectivos para protofibrillas/oligómeros de amiloide-P truncado en el extremo N |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120100129A1 (enExample) |
| EP (2) | EP2448968B1 (enExample) |
| JP (3) | JP2012532094A (enExample) |
| AU (1) | AU2010267640B2 (enExample) |
| CA (1) | CA2765602C (enExample) |
| CY (1) | CY1124034T1 (enExample) |
| DK (1) | DK2448968T3 (enExample) |
| ES (1) | ES2864049T3 (enExample) |
| HR (1) | HRP20210611T1 (enExample) |
| HU (1) | HUE053949T2 (enExample) |
| LT (1) | LT2448968T (enExample) |
| PL (1) | PL2448968T3 (enExample) |
| PT (1) | PT2448968T (enExample) |
| SI (1) | SI2448968T1 (enExample) |
| SM (1) | SMT202100237T1 (enExample) |
| WO (1) | WO2011001366A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| BRPI0709050B1 (pt) | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| EP2539366B1 (en) | 2010-02-26 | 2017-11-08 | BioArtic Neuroscience AB | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| CN103459421B (zh) * | 2011-03-16 | 2017-07-14 | 前体生物药物股份公司 | 诊断性抗体测定 |
| HRP20210680T1 (hr) | 2014-07-10 | 2021-06-11 | Bioarctic Ab | POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL |
| CN107849125A (zh) | 2015-07-21 | 2018-03-27 | 生命北极神经科学公司 | 用于治疗靶向聚集的肽的创伤性脑损伤的方法 |
| CA3028035A1 (en) | 2016-07-14 | 2018-01-18 | Bioarctic Ab | Brain delivery protein |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| CA3107370A1 (en) | 2018-07-24 | 2020-01-30 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| JPWO2021006212A1 (enExample) * | 2019-07-08 | 2021-01-14 | ||
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| HUE072262T2 (hu) | 2020-06-26 | 2025-11-28 | Bioarctic Ab | Alfa-szinuklein protofibrillum-kötõ antitestek |
| AU2022307687A1 (en) | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| EP4395821A1 (en) | 2021-08-30 | 2024-07-10 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| JP2025506389A (ja) | 2022-02-02 | 2025-03-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ｐ－タウ１８１レベルを使用した治療方法 |
| EP4638494A1 (en) | 2022-12-22 | 2025-10-29 | BioArctic AB | Antibody which binds to abetape3 |
| TW202607032A (zh) | 2024-06-20 | 2026-02-16 | 瑞典商生物極公司 | 雙特異性結合分子 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| EP1571158B1 (en) * | 1999-08-04 | 2009-10-14 | University Of Southern California | Globular assembly of amyloid beta protein and uses thereof |
| EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| EP1523499A2 (en) * | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| PT1737891E (pt) * | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| GB0413726D0 (en) * | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| GEP20115195B (en) * | 2004-07-30 | 2011-04-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and use thereof |
| BRPI0709050B1 (pt) * | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| EP2207568B1 (en) * | 2007-11-16 | 2017-05-31 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| DK2282758T3 (en) * | 2008-04-29 | 2019-02-25 | Bioarctic Ab | ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS |
-
2010
- 2010-06-29 US US13/379,523 patent/US20120100129A1/en not_active Abandoned
- 2010-06-29 LT LTEP10739701.0T patent/LT2448968T/lt unknown
- 2010-06-29 AU AU2010267640A patent/AU2010267640B2/en active Active
- 2010-06-29 PL PL10739701T patent/PL2448968T3/pl unknown
- 2010-06-29 PT PT107397010T patent/PT2448968T/pt unknown
- 2010-06-29 HU HUE10739701A patent/HUE053949T2/hu unknown
- 2010-06-29 CA CA2765602A patent/CA2765602C/en active Active
- 2010-06-29 JP JP2012516964A patent/JP2012532094A/ja not_active Withdrawn
- 2010-06-29 HR HRP20210611TT patent/HRP20210611T1/hr unknown
- 2010-06-29 ES ES10739701T patent/ES2864049T3/es active Active
- 2010-06-29 SM SM20210237T patent/SMT202100237T1/it unknown
- 2010-06-29 EP EP10739701.0A patent/EP2448968B1/en active Active
- 2010-06-29 EP EP21153326.0A patent/EP3892633A1/en active Pending
- 2010-06-29 WO PCT/IB2010/052947 patent/WO2011001366A1/en not_active Ceased
- 2010-06-29 SI SI201032068T patent/SI2448968T1/sl unknown
- 2010-06-29 DK DK10739701.0T patent/DK2448968T3/da active
-
2017
- 2017-04-19 JP JP2017083057A patent/JP6884025B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142344A patent/JP2019218362A/ja active Pending
-
2021
- 2021-04-27 CY CY20211100361T patent/CY1124034T1/el unknown
-
2022
- 2022-12-15 US US18/066,998 patent/US20230295283A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010267640A1 (en) | 2012-01-19 |
| CY1124034T1 (el) | 2022-05-27 |
| CA2765602C (en) | 2021-05-25 |
| SMT202100237T1 (it) | 2021-05-07 |
| SI2448968T1 (sl) | 2021-07-30 |
| HUE053949T2 (hu) | 2021-08-30 |
| JP2012532094A (ja) | 2012-12-13 |
| JP2019218362A (ja) | 2019-12-26 |
| EP2448968A1 (en) | 2012-05-09 |
| JP6884025B2 (ja) | 2021-06-09 |
| LT2448968T (lt) | 2021-05-10 |
| PL2448968T3 (pl) | 2021-09-13 |
| HRP20210611T1 (hr) | 2021-05-28 |
| PT2448968T (pt) | 2021-04-30 |
| CA2765602A1 (en) | 2011-01-06 |
| EP3892633A1 (en) | 2021-10-13 |
| WO2011001366A1 (en) | 2011-01-06 |
| AU2010267640B2 (en) | 2015-03-05 |
| US20230295283A1 (en) | 2023-09-21 |
| US20120100129A1 (en) | 2012-04-26 |
| DK2448968T3 (da) | 2021-04-12 |
| EP2448968B1 (en) | 2021-01-27 |
| JP2017197531A (ja) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230295283A1 (en) | N-terminal truncated protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's | |
| DK2282758T3 (en) | ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS | |
| KR101600095B1 (ko) | 모노클로널 항 베타 아밀로이드 항체 | |
| KR101591206B1 (ko) | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 | |
| JP6174667B2 (ja) | 病理学的タウタンパク質の免疫学的標的化方法 | |
| ES2661925T3 (es) | Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías | |
| JP7204235B2 (ja) | 活性型α－シヌクレインに結合する抗体 | |
| WO2009048539A2 (en) | Monoclonal antibody | |
| Goñi et al. | Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model | |
| CN101325972B (zh) | 具有治疗性质的Aβ1-42特异性单克隆抗体 | |
| JP7151985B2 (ja) | 抗プロパノイル化アミロイドβタンパク質抗体 | |
| JP2022528459A (ja) | 融合構築物及びその使用 | |
| HK40057935A (en) | Antibodies selective for n-terminaltruncated amyloid-p protofibrils/oligomers | |
| Herline | Passive Immunization to Improve Cognition and Reduce Pathological Species in a Mouse Model of Alzheimer's Disease | |
| HK1124532B (zh) | 具有治疗性质的Aβ1-42特异性单克隆抗体 |